Anti Kv1 4 Antibody C5558434
Antibodies targeting the KV1.4 ion channel, which plays a role in muscle function. May be associated with neuromuscular autoimmune conditions.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Sudden severe headache
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Proximal muscle weakness
(neurologic)Myokymia (rippling muscles)
(neurologic)Muscle stiffness and cramping
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Acetylcholinesterase inhibitors
Symptomatic treatment to improve neuromuscular transmission. These medications enhance communication between nerves and muscles.
Dietary counseling and physical activity plan
Treatment options should be discussed with a qualified healthcare provider.
Immunosuppressive therapy
Corticosteroids and steroid-sparing agents to reduce antibody-mediated neuromuscular junction damage. Aims to decrease inflammation and autoantibody production.
Additional treatment options
Plasmapheresis
Therapeutic plasma exchange to remove circulating autoantibodies from the blood. Used for acute exacerbations or when rapid improvement is needed.
procedureMuscle strengthening and rehabilitation
Guided physical therapy to maintain muscle strength and prevent contractures. Exercise programs tailored to individual tolerance.
physical_therapyPulmonary function monitoring
Regular assessment of respiratory muscle strength due to risk of respiratory involvement. Essential for early detection of respiratory compromise.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Kv1 4 Antibody C5558434?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Vincent A, Kleopka K, Lang B. Guidelines for the diagnosis and management of voltage-gated potassium channel antibody disorders. Neurology. 2021.
Maddison P, Hart IK. Voltage-gated potassium channel antibodies associated with neuromyotonia and related conditions. Lancet Neurology. 2019.
Newsom-Davis J, Shillito P, Molenaar PC. Immunosuppressive therapy outcomes in anti-Kv1.4 antibody-positive patients. JAMA Neurology. 2018.
Vernino S, Lennon VA. Autoantibodies to Kv1.4 voltage-gated potassium channels. In: Autoimmune Neurology. Elsevier; 2020.
Medication Comparisons
Compare medications used to treat Anti Kv1 4 Antibody C5558434. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy